StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
MyoKardia (MYOK) PT Raised to $84 at Wedbush
January 2, 2019 2:18 PM
Wedbush analyst David Nierengarten raised ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst PT Change
Next Articles
MyoKardia (MYOK) Re-acquires Global Rights to Mavacamten and MYK-491 Programs from Sanofi (SNY)
January 2, 2019 8:13 AM
MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
January 2, 2019 8:00 AM